Robert F Storey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5591414/publications.pdf

Version: 2024-02-01

365 papers	59,628 citations	5248 83 h-index	981 237 g-index
410 all docs	410 docs citations	410 times ranked	34497 citing authors

#	Article	IF	Citations
1	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2009, 361, 1045-1057.	13.9	6,019
2	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	1.0	5,890
3	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	1.0	4,210
4	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	1.0	3,048
5	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2999-3054.	1.0	2,995
6	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
7	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	1.2	2,558
8	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	1.0	2,447
9	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	1.0	2,246
10	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	13.9	1,585
11	Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. Circulation, 2009, 120, 2577-2585.	1.6	1,035
12	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1509-1524.	13.9	833
13	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet, The, 2010, 376, 1320-1328.	6.3	709
14	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine, 2012, 366, 20-33.	13.9	701
15	Expert position paper on air pollution and cardiovascular disease. European Heart Journal, 2015, 36, 83-93.	1.0	646
16	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet, The, 2010, 375, 283-293.	6.3	624
17	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 3-46.	0.4	561
18	Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, 2019, 381, 1411-1421.	13.9	542

#	Article	IF	Citations
19	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 2014, 371, 1016-1027.	13.9	538
20	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	1.0	490
21	Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. Circulation, 2010, 122, 2131-2141.	1.6	474
22	Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2007, 50, 1844-1851.	1.2	471
23	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2011, 57, 672-684.	1.2	457
24	Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2007, 50, 1852-1856.	1.2	438
25	Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. Circulation, 2010, 121, 1188-1199.	1.6	419
26	Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation, 2011, 124, 544-554.	1.6	397
27	The role of platelets in inflammation. Thrombosis and Haemostasis, 2015, 114, 449-458.	1.8	391
28	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2010, 31, 3006-3016.	1.0	389
29	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	1.1	366
30	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2009, 157, 599-605.	1.2	363
31	Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Circulation, 2010, 122, 1056-1067.	1.6	354
32	Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 56, 1456-1462.	1.2	339
33	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2011, 32, 2933-2944.	1.0	335
34	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2719-2728.	1.2	303
35	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€“Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
36	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	0.6	261

#	Article	IF	Citations
37	The central role of the P 2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. British Journal of Haematology, 2000, 110, 925-934.	1.2	254
38	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ: British Medical Journal, 2011, 342, d3527-d3527.	2.4	246
39	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35, 209-215.	1.0	224
40	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. Europace, 2019, 21, 192-193.	0.7	209
41	Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal, 2011, 32, 2922-2932.	1.0	203
42	Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 680-688.	0.9	198
43	Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes. Thrombosis and Haemostasis, 2001, 85, 401-407.	1.8	189
44	ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 173.	0.4	183
45	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 1-44.	0.4	180
46	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	6.1	180
47	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	6.1	180
48	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUSâ€“TIMI 54. Journal of the American College of Cardiology, 2016, 67, 2732-2740.	1.2	179
49	Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor. Circulation, 2012, 125, 978-986.	1.6	176
50	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2015, 36, ehv304.	1.0	175
51	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal, 2014, 35, 2083-2093.	1.0	171
52	Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal, 2011, 32, 2945-2953.	1.0	169
53	Association of MicroRNAs and YRNAs With Platelet Function. Circulation Research, 2016, 118, 420-432.	2.0	167
54	Biology and Pharmacology of the Platelet P2Y12 Receptor. Current Pharmaceutical Design, 2006, 12, 1255-1259.	0.9	165

#	Article	IF	Citations
55	First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. Circulation: Cardiovascular Genetics, 2010, 3, 556-566.	5.1	163
56	Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study. Journal of the American College of Cardiology, 2010, 56, 185-193.	1.2	157
57	Inhibition of ADP-induced P-selectin Expression and Platelet-Leukocyte Conjugate Formation by Clopidogrel and the P2Y12 Receptor Antagonist AR-C69931MX but not Aspirin. Thrombosis and Haemostasis, 2002, 88, 488-494.	1.8	147
58	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thrombosis and Haemostasis, 2014, 112, 781-782.	1.8	142
59	Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets, 2002, 13, 407-413.	1.1	140
60	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 2017, 70, 1760-1776.	1.2	140
61	Update on lipids, inflammation and atherothrombosis. Thrombosis and Haemostasis, 2011, 105, S34-S42.	1.8	138
62	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets, 2014, 25, 517-525.	1.1	138
63	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y₁₂inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 2016, 37, 1133-1142.	1.0	138
64	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal, 2016, 37, 1325-1333.	1.0	137
65	Response Variability to P2Y12 Receptor Inhibitors. JACC: Cardiovascular Interventions, 2013, 6, 1111-1128.	1.1	128
66	Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes. Circulation, 2013, 128, 1055-1065.	1.6	118
67	The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and) Tj ETQq1 1 0.784314 rgBT /Overlock	1.2	112
68	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation, 2012, 125, 2914-2921.	1.6	112
69	Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thrombosis and Haemostasis, 2005, , .	1.8	110
70	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal, 2018, 39, 1078-1085.	1.0	109
71	Platelet Inhibition With Ticagrelor 60ÂmgÂVersus 90 mg Twice Daily in theÂPEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 2016, 67, 1145-1154.	1.2	108
72	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 2015, 36, 1901-1912.	1.0	107

#	Article	IF	Citations
73	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y. Europace, 2017, 19, 1757-1758.	0.7	107
74	Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets, 2001, 12, 443-447.	1.1	106
75	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. European Heart Journal, 2018, 39, 1672-1686f.	1.0	106
76	Platelet P2Y ₁₂ Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2562-2570.	1.1	105
77	Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thrombosis and Haemostasis, 2005, 94, 831-8.	1.8	104
78	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Nonâ€“ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. Circulation, 2014, 129, 293-303.	1.6	100
79	P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. Thrombosis and Haemostasis, 2016, 116, 369-378.	1.8	97
80	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. JAMA Cardiology, 2019, 4, 1092.	3.0	97
81	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirinâ€“Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal, 2014, 167, 437-444.e5.	1.2	89
82	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. JAMA Cardiology, 2016, 1, 425.	3.0	88
83	Timing of Staged Nonculprit ArteryÂRevascularization in Patients WithÂST-Segment Elevation MyocardialÂInfarction. Journal of the American College of Cardiology, 2019, 74, 2713-2723.	1.2	88
84	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	6.1	87
85	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2017, 38, ehw454.	1.0	86
86	Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thrombosis and Haemostasis, 2013, 110, 609-615.	1.8	82
87	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology, 2015, 22, 734-742.	0.8	82
88	Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2020, 5, 881.	3.0	82
89	Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2012, 60, 1623-1630.	1.2	80
90	Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thrombosis and Haemostasis, 2010, 103, 1210-1217.	1.8	79

#	Article	IF	Citations
91	Effect of P2Y12 inhibitors on inflammation and immunity. Thrombosis and Haemostasis, 2015, 114, 490-497.	1.8	76
92	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. American Heart Journal, 2011, 162, 160-165.	1.2	75
93	Efficacy and Safety of Ticagrelor OverÂTime in Patients With Prior MI inÂPEGASUS-TIMI 54. Journal of the American College of Cardiology, 2017, 70, 1368-1375.	1.2	74
94	Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. Circulation, 2013, 127, 673-680.	1.6	72
95	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2014, 35, 1541-1550.	1.0	70
96	Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European Heart Journal, 2014, 35, 1510-1514.	1.0	70
97	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal, 2016, 37, ehv482.	1.0	70
98	Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention, 2013, 9, 62-69.	1.4	66
99	Common sequence variations in the P2Y12and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets, 2006, 17, 250-258.	1.1	65
100	Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Circulation, 2018, 138, 1290-1300.	1.6	65
101	The active metabolite of prasugrel effectively blocks the platelet P2Y₁₂receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets, 2008, 19, 125-133.	1.1	64
102	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 2020, 120, 538-564.	1.8	64
103	Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations inP2RY12, P2RY1,andITGB3. Platelets, 2009, 20, 341-348.	1.1	63
104	Nonculprit Lesion Plaque Morphology in Patients With ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2020, 13, e008768.	1.4	63
105	Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.6	63
106	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 1160.	3.0	57
107	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart, 2016, 102, 617-625.	1.2	56
108	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients WithÂMultivessel Coronary Disease. Journal of the American College of Cardiology, 2018, 71, 489-496.	1.2	56

#	Article	IF	Citations
109	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention, 2015, 11, 737-745.	1.4	54
110	Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. Journal of Thrombosis and Haemostasis, 2011, 9, 1730-1737.	1.9	53
111	Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromesâ€"Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2012, 164, 334-342.e1.	1.2	53
112	Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 64, 1270-1280.	1.2	53
113	Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease. Clinical Pharmacokinetics, 2012, 51, 397-409.	1.6	52
114	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal, 2020, 41, 3132-3140.	1.0	52
115	Comparison of Two Strategies for the Management of Antiplatelet Therapy During Urgent Surgery. Annals of Thoracic Surgery, 2005, 80, 149-152.	0.7	51
116	Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thrombosis and Haemostasis, 2016, 116, 96-102.	1.8	51
117	Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1187-1199.	1.8	51
118	Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel. Clinical Cardiology, 2010, 33, 206-212.	0.7	50
119	Ticagrelor Effectively and Reversibly Blocks Murine Platelet P2Y ₁₂ -Mediated Thrombosis and Demonstrates a Requirement for Sustained P2Y ₁₂ Inhibition to Prevent Subsequent Neointima. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2385-2391.	1.1	50
120	Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. American Heart Journal, 2014, 168, 530-536.	1.2	50
121	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology, 2020, 76, 162-171.	1.2	50
122	Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thrombosis and Haemostasis, 2002, 88, 488-94.	1.8	49
123	PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets, 2005, 16, 340-345.	1.1	48
124	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical managementâ€"a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2017, 38, ehv676.	1.0	48
125	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Journal of the American College of Cardiology, 2014, 63, 1493-1499.	1.2	47
126	Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. BMJ, The, 2021, 374, n2106.	3.0	47

#	Article	IF	Citations
127	Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovascular Research, 2014, 102, 429-435.	1.8	45
128	Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 555-560.	0.4	45
129	Inhibitory effects of P2Y12receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets, 2005, 16, 73-80.	1.1	43
130	Glycoprotein IIb/IIIa and P2Y12receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets, 2005, 16, 398-407.	1.1	43
131	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors â€“ is an algorithm the answer?. Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	43
132	Stabilizing Role of Platelet P2Y12 Receptors in Shear-Dependent Thrombus Formation on Ruptured Plaques. PLoS ONE, 2010, 5, e10130.	1.1	42
133	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. American Heart Journal, 2015, 169, 879-889.e7.	1.2	42
134	Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 3-12.	0.4	41
135	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Human Molecular Genetics, 2016, 25, 1447-1456.	1.4	41
136	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology, 2014, 63, 1048-1057.	1.2	40
137	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. Circulation, 2016, 134, 861-871.	1.6	40
138	Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and Haemostasis, 2011, 105, S75-S81.	1.8	39
139	ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation, 2012, 125, 514-521.	1.6	39
140	Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Nonâ€“ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study. Clinical Chemistry, 2012, 58, 190-199.	1.5	38
141	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart, 2014, 100, 1762-1769.	1.2	38
142	Inhibitory mechanisms of very lowâ€“dose rivaroxaban in nonâ€“ST-elevation myocardial infarction. Blood Advances, 2018, 2, 715-730.	2.5	38
143	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, 4, e002490.	1.6	37
144	A Whole Blood Assay of Inhibition of Platelet Aggregation by Glycoprotein IIb/IIIa Antagonists: Comparison with other Aggregation Methodologies. Thrombosis and Haemostasis, 1999, 82, 1307-1311.	1.8	36

#	Article	IF	Citations
145	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 2017, 186, 91-99.	1.2	36
146	Platelet Function Testing in Atherothrombotic Disease. Current Pharmaceutical Design, 2012, 18, 5379-5391.	0.9	35
147	Angiographic Outcomes in the PLATO TrialÂ(Platelet Inhibition and PatientÂOutcomes). JACC: Cardiovascular Interventions, 2013, 6, 671-683.	1.1	35
148	Platelet function testing in acute cardiac care â€“ is there a role for prediction or prevention of stent thrombosis and bleeding?. Thrombosis and Haemostasis, 2015, 113, 221-230.	1.8	33
149	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y ₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. Journal of the American Heart Association, 2019, 8, e011139.	1.6	33
150	Gut MicrobiotaâEDependent Trimethylamine Nâ€oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2020, 9, e015331.	1.6	32
151	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
152	Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets, 2004, 15, 465-474.	1.1	31
153	GuÃa de prÃ¡ctica clÃnica de la ESC para el manejo del sÃndrome coronario agudo en pacientes sin elevaciÃ³n persistente del segmento ST. Revista Espanola De Cardiologia, 2012, 65, 173.e1-173.e55.	0.6	31
154	Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgraduate Medical Journal, 2014, 90, 520-528.	0.9	31
155	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors â€“ is an algorithm the answer?. Thrombosis and Haemostasis, 2015, 113, 37-52.	1.8	31
156	Effect of Pre-Hospital Ticagrelor During the FirstÂ24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 646-656.	1.1	31
157	Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y₁₂receptorsin vitro. Platelets, 2016, 27, 191-195.	1.1	31
158	Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular Diabetology, 2020, 19, 3.	2.7	31
159	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 125-140.	1.4	31
160	Platelet function testing and prediction of procedural bleeding risk. Thrombosis and Haemostasis, 2013, 109, 817-824.	1.8	30
161	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	6.1	30
162	Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. Vascular Pharmacology, 2015, 71, 201-207.	1.0	29

#	Article	IF	Citations
163	Monitoring Antiplatelet Therapy. Seminars in Thrombosis and Hemostasis, 2017, 43, 311-319.	1.5	29
164	Antithrombotic therapy in diabetes: which, when, and for how long?. European Heart Journal, 2021, 42, 2235-2259.	1.0	29
165	Development and Clinical use of Prasugrel and Ticagrelor. Current Pharmaceutical Design, 2012, 18, 5240-5260.	0.9	27
166	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. Thrombosis and Haemostasis, 2014, 112, 883-891.	1.8	27
167	The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) â€" a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial. Trials, 2016, 17, 579.	0.7	27
168	Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 2016, 102, 783-789.	1.2	27
169	Growth Differentiation Factor 15 at 1ÂMonth After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 2017, 6, .	1.6	27
170	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632.	1.0	27
171	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology, 2020, 5, 1255.	3.0	27
172	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. Thrombosis and Haemostasis, 2020, 120, 412-422.	1.8	27
173	Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. Cmaj, 2012, 184, 1135-1142.	0.9	26
174	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Nonâ€"ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 573-584.	1.5	26
175	Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromesâ€"Results from the PLATO Trial. Value in Health, 2013, 16, 574-580.	0.1	25
176	NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Genetics, 2015, 8, 498-506.	5.1	25
177	C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2402-2410.	1.1	25
178	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 200-206.	1.4	25
179	Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 2019, 30, 148-157.	1.1	25
180	Clopidogrel in acute coronary syndrome: to genotype or not?. Lancet, The, 2009, 373, 276-278.	6.3	24

#	Article	IF	Citations
181	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis â€“ Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 2016, 115, 685-711.	1.8	24
182	Antithrombotics. Journal of the American College of Cardiology, 2019, 74, 699-711.	1.2	24
183	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 2016, 177, 1-8.	1.2	23
184	Cost-Effectiveness of Long-TermÂTicagrelor in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology, 2017, 70, 527-538.	1.2	23
185	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. American Journal of Cardiovascular Drugs, 2019, 19, 173-183.	1.0	23
186	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. European Heart Journal, 2018, 39, e1-e33.	1.0	22
187	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22
188	Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 2018, 118, 1250-1256.	1.8	22
189	Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin. Thrombosis Research, 2005, 115, 301-307.	0.8	21
190	PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. Platelets, 2015, 26, 236-242.	1.1	21
191	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thrombosis and Haemostasis, 2017, 117, 940-947.	1.8	21
192	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. EuroIntervention, 2021, 17, 59-66.	1.4	21
193	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. European Heart Journal, 2021, 42, 2973-2985.	1.0	21
194	Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. International Journal of Clinical Pharmacology and Therapeutics, 2016, 54, 666-674.	0.3	21
195	Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 294-302.	1.1	20
196	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. Journal of the American College of Cardiology, 2020, 76, 1277-1286.	1.2	20
197	Cystatin Câ€“ and Creatinine-Based Estimates of Renal Function and Their Value for Risk Prediction in Patients with Acute Coronary Syndrome: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study. Clinical Chemistry, 2013, 59, 1369-1375.	1.5	19
198	Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics. International Journal of Cardiology, 2016, 202, 167-173.	0.8	19

#	Article	IF	Citations
199	Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets, 2020, 31, 174-178.	1.1	19
200	Current strategies in antiplatelet therapy â€" Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. , 2010, 127, 95-107.		18
201	Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. Vascular Pharmacology, 2016, 84, 25-27.	1.0	18
202	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2017, 44, 145-153.	1.0	18
203	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. EuroIntervention, 2017, 13, 69-77.	1.4	18
204	Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2014, 7, 19-28.	1.1	17
205	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Nonâ€"ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). American Journal of Cardiology, 2014, 113, 936-944.	0.7	17
206	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. American Heart Journal, 2014, 168, 96-102.e2.	1.2	17
207	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 500-510.	0.4	17
208	The IL-1RI Co-Receptor TILRR (FREM1ÂIsoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease. JACC Basic To Translational Science, 2017, 2, 398-414.	1.9	17
209	Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. American Heart Journal, 2019, 215, 157-166.	1.2	17
210	Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 208-217.	0.4	17
211	Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition. International Journal of Molecular Sciences, 2020, 21, 2897.	1.8	17
212	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Longâ€Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008.	1.6	17
213	Antiplatelet therapy and vascular disease: an update. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 249-275.	1.0	16
214	Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive â€˜real-worldâ€™ patients. Platelets, 2017, 28, 767-773.	1.1	16
215	Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in nonâ€"STâ€segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology, 2017, 40, 390-398.	0.7	16
216	Interleukinâ€18 in patients with acute coronary syndromes. Clinical Cardiology, 2019, 42, 1202-1209.	0.7	16

#	Article	IF	Citations
217	Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?. Thrombosis and Haemostasis, 2019, 119, 1583-1589.	1.8	16
218	Pharmacokineticâ€“pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. British Journal of Clinical Pharmacology, 2019, 85, 413-421.	1.1	16
219	Plaque Burden and 1-Year Outcomes inÂAcute Chest Pain. JACC: Cardiovascular Imaging, 2022, 15, 1916-1925.	2.3	16
220	New P2Y12 inhibitors. Heart, 2011, 97, 1262-1267.	1.2	15
221	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. Cardiovascular Research, 2019, 115, 1512-1518.	1.8	15
222	Ticagrelor: clinical development and future potential. Reviews in Cardiovascular Medicine, 2021, 22, 373.	0.5	15
223	Platelets: Developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. Platelets, 2008, 19, 239-251.	1.1	14
224	Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 254-262.	0.4	14
225	Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes. Thrombosis and Haemostasis, 2016, 116, 1079-1088.	1.8	14
226	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 2020, 109, 930-943.	1.5	14
227	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clinical Research in Cardiology, 2020, 109, 1125-1139.	1.5	14
228	Evolving pattern of platelet P2Y₁₂inhibition in patients with acute coronary syndromes. Platelets, 2014, 25, 416-422.	1.1	13
229	Cangrelor for the management and prevention of arterial thrombosis. Expert Review of Cardiovascular Therapy, 2016, 14, 991-999.	0.6	13
230	Ticagrelor. Interventional Cardiology Clinics, 2017, 6, 49-55.	0.2	13
231	Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events. European Heart Journal, 2022, 43, 153-163.	1.0	13
232	Clopidogrel resistance. Catheterization and Cardiovascular Interventions, 2004, 63, 397-398.	0.7	12
233	Variability of response to antiplatelet therapy. Country Review Ukraine, 2008, 10, A21-A27.	0.8	12
234	ESC/EAS Guidelines for the management of dyslipidaemias. Revista Espanola De Cardiologia (English Ed) Tj ETQq0 0 0 rgBT /Overlock 10	0.4	12

#	Article	IF	Citations
235	The future of P2Y₁₂ receptor antagonists. Platelets, 2015, 26, 392-398.	1.1	12
236	Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 313-322.	0.4	12
237	Novel approaches to P2Y₁₂ inhibition and aspirin dosing. Platelets, 2021, 32, 7-14.	1.1	12
238	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 153-163.	0.4	12
239	The right oral antithrombotics in acute coronary syndromes. Lancet, The, 2009, 374, 1947-1948.	6.3	11
240	Exploring Mechanisms of Graft Occlusion. Journal of the American College of Cardiology, 2011, 57, 1078-1080.	1.2	11
241	Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 2015, 170, 465-470.	1.2	11
242	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis, 2019, 48, 563-569.	1.0	11
243	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. Thrombosis and Haemostasis, 2020, 120, 065-074.	1.8	11
244	Antithrombotic therapy for patients with chronic coronary syndromes. Heart, 2021, 107, 925-933.	1.2	11
245	Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 416-424.	0.3	11
246	Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 24-38.	0.4	10
247	Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay. Thrombosis and Haemostasis, 2013, 109, 550-555.	1.8	10
248	Genetics of Response to Antiplatelet Therapy. Progress in Molecular Biology and Translational Science, 2014, 124, 123-153.	0.9	10
249	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. International Journal of Cardiology, 2014, 170, e59-e62.	0.8	10
250	Can we improve the efficacy of low-dose aspirin?. Thrombosis and Haemostasis, 2014, 112, 1077-1078.	1.8	10
251	Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex. American Journal of Medicine, 2015, 128, 914.e11-914.e19.	0.6	10
252	Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. American Heart Journal, 2018, 196, 56-64.	1.2	10

#	Article	IF	Citations
253	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	1.4	10
254	New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 2059.	1.0	10
255	International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. Journal of Thrombosis and Thrombolysis, 2021, 52, 992-998.	1.0	10
256	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 2017, 117, 1093-1100.	1.8	9
257	Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. Haematologica, 2021, 106, 1616-1623.	1.7	9
258	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2021, 143, 1215-1223.	1.6	9
259	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets, 2022, 33, 425-431.	1.1	9
260	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 343-355.	0.4	9
261	Ticagrelor: from concept to clinical evaluation. Biomarkers in Medicine, 2011, 5, 53-62.	0.6	8
262	Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patientsâ€"Results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal, 2012, 164, 728-734.	1.2	8
263	TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. Journal of the American College of Cardiology, 2015, 66, B36.	1.2	8
264	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e002951.	2.1	8
265	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient) Tj ETQq1 1 0.784314 rgBT /Overl	2.1	8
266	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUSâ€"TIMI 54. Journal of the American Heart Association, 2018, 7, e009260.	1.6	8
267	Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y₁₂ receptor antagonist. Expert Opinion on Emerging Drugs, 2020, 25, 1-6.	1.0	8
268	Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 847-856.	1.4	8
269	New developments in antiplatelet therapy. Country Review Ukraine, 2008, 10, D30-D37.	0.8	7
270	Ticagrelor: agonising over its mechanisms of action. Blood, 2016, 128, 2595-2597.	0.6	7

#	Article	IF	Citations
271	Ticagrelor in patients with heart failure after acute coronary syndromesâ€"Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2019, 213, 57-65.	1.2	7
272	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 222-230.	1.4	7
273	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2020, 9, e015785.	1.6	7
274	Longâ€Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	1.6	7
275	Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. Platelets, 2022, 33, 141-146.	1.1	7
276	Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy. American Journal of Medicine, 2013, 126, 723-729.e1.	0.6	6
277	Ticagrelor in Patients With Acute Coronary Syndromes and Stroke. Stroke, 2013, 44, 1477-1479.	1.0	6
278	Exposureâ€Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction. Journal of Clinical Pharmacology, 2017, 57, 573-583.	1.0	6
279	Aspirin and Primary Prevention in Patients with Diabetesâ€"A Critical Evaluation of Available Randomized Trials and Meta-Analyses. Thrombosis and Haemostasis, 2019, 119, 1573-1582.	1.8	6
280	The long journey of individualizing antiplatelet therapy after acute coronary syndromes. European Heart Journal, 2020, 41, 3546-3548.	1.0	6
281	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. Cardiovascular Drugs and Therapy, 2021, 35, 549-559.	1.3	6
282	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003006.	1.6	6
283	Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention. Thrombosis and Haemostasis, 2006, 95, 997-1002.	1.8	5
284	More transparency for a therapeutic window in platelet P2Y₁₂inhibition?. European Heart Journal, 2015, 36, 1714-1717.	1.0	5
285	Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 2016, 134, 793-796.	1.6	5
286	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. American Journal of Cardiology, 2017, 119, 1135-1140.	0.7	5
287	Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 2019, 40, 1971-1974.	1.0	5
288	Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets, 2020, 31, 945-951.	1.1	5

#	Article	IF	Citations
289	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis, 2020, 293, 35-41.	0.4	5
290	Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. European Heart Journal Supplements, 2020, 22, M26-M34.	0.0	5
291	Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient) Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	5
292	Opiates and Clopidogrel Efficacy. Journal of the American College of Cardiology, 2020, 75, 301-303.	1.2	5
293	A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia. Molecular and Cellular Proteomics, 2021, 20, 100021.	2.5	5
294	Platelets and the Endothelium. JACC Basic To Translational Science, 2021, 6, 219-221.	1.9	5
295	Cangrelor succeeds, at last, in PCI. Nature Reviews Cardiology, 2013, 10, 302-304.	6.1	4
296	Utilisation of novel anti-platelet agents: evidence, guidelines and proven patientsâ€™ value. Thrombosis and Haemostasis, 2014, 112, 12-14.	1.8	4
297	215â€…Ticagrelor Inhibits Release of Pro-inflammatory Cytokines TNF and IL-6 during Human Endotoxaemia. Heart, 2014, 100, A117.3-A118.	1.2	4
298	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. International Journal of Cardiology, 2014, 176, 300-302.	0.8	4
299	Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Current Cardiology Reports, 2016, 18, 48.	1.3	4
300	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.2	4
301	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 2019, 30, 579-588.	1.1	4
302	Preâ€hospital administration of ticagrelor in diabetic patients with STâ€elevation myocardial infarction undergoing primary angioplasty: A subâ€analysis of the ATLANTIC trial. Catheterization and Cardiovascular Interventions, 2019, 93, E369-E377.	0.7	4
303	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology, 2021, 324, 30-37.	0.8	4
304	Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis. EuroIntervention, 2018, 14, 789-797.	1.4	4
305	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	0.7	4
306	Resumption of Antiplatelet Therapy after Major Bleeding. Thrombosis and Haemostasis, 2023, 123, 135-149.	1.8	4

#	Article	IF	Citations
307	Clinical experience with antithrombotic drugs acting on purine receptor pathways. Drug Development Research, 2001, 52, 202-212.	1.4	3
308	TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY. Journal of the American College of Cardiology, 2010, 55, A108.E1007.	1.2	3
309	Choosing a perspective on mortality with DAPT. European Heart Journal, 2016, 37, ehv610.	1.0	3
310	Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. International Journal of Cardiology, 2017, 244, 49-53.	0.8	3
311	BÎ²Arg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes. Thrombosis and Haemostasis, 2017, 117, 295-302.	1.8	3
312	Dual antiplatelet therapy in the â€˜real worldâ€™. Heart, 2018, 104, 1555-1556.	1.2	3
313	Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets, 2021, 32, 555-559.	1.1	3
314	Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continues. Heart, 2021, 107, 1111-1112.	1.2	3
315	Extended dual antiplatelet therapy with ticagrelor 60â€‰mg in patients with prior myocardial infarction: The design of <scp>ALETHEIA</scp>, a multiâ€country observational study. Clinical Cardiology, 2021, 44, 1333-1343.	0.7	3
316	What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus?. Diabetes and Vascular Disease Research, 2010, 7, 249-250.	0.9	2
317	Education in atherothrombosis. Thrombosis and Haemostasis, 2011, 105, S1-S2.	1.8	2
318	Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes. Platelets, 2013, 24, 643-648.	1.1	2
319	Response to Letter Regarding Article, â€œStent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trialâ€. Circulation, 2014, 129, e494-5.	1.6	2
320	Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period. Platelets, 2015, 26, 271-273.	1.1	2
321	The challenges of antithrombotic therapy in patients with left ventricular thrombosis. European Heart Journal, 2018, 39, 209-211.	1.0	2
322	Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. European Heart Journal, 2020, 41, 483-484.	1.0	2
323	Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segmentâ€“Elevation Myocardial Infarction: Insights From the COMPLETE Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010458.	1.4	2
324	Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?. Cardiovascular Research, 2021, 117, e123-e125.	1.8	2

#	Article	IF	Citations
325	Ticagrelor monotherapy in CKD: better safety at what price?. European Heart Journal, 2021, 42, 4694-4696.	1.0	2
326	Thrombotic response. , 2018, , 1227-1230.		2
327	Abstract 11594: Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. Circulation, 2015, 132, .	1.6	2
328	The cardiac complications of COVID-19: many publications, multiple uncertainties. Vascular Biology (Bristol, England), 2020, 2, R105-R114.	1.2	2
329	Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 336-349.	0.4	2
330	A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. Cardiovascular Diabetology, 2021, 20, 238.	2.7	2
331	THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL. Journal of the American College of Cardiology, 2010, 55, A108.E1006.	1.2	1
332	Response to Letter Regarding Article, â€œAssociation of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATOâ€• Circulation, 2012, 126, .	1.6	1
333	Reply. Journal of the American College of Cardiology, 2015, 65, 516-518.	1.2	1
334	72â€…Offset of ticagrelor prior to coronary artery bypass graft surgery (cabg) surgery. Heart, 2017, 103, A53.2-A54.	1.2	1
335	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. Thrombosis and Haemostasis, 2018, 118, 427-429.	1.8	1
336	Reply. Journal of the American College of Cardiology, 2018, 71, 108.	1.2	1
337	Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. The Cochrane Library, 0, , .	1.5	1
338	Randomised Controlled Trial of Early CT Coronary Angiography in Patients With Suspected Acute Coronary Syndrome. SSRN Electronic Journal, 0, , .	0.4	1
339	The cardiac complications of COVID-19: many publications, multiple uncertainties. Vascular Biology (Bristol, England), 2020, 2, R105-R114.	1.2	1
340	O4 Heparins sensitize platelets to responses mediated via both the P27 and the P2Y1 receptor pathways. Blood Coagulation and Fibrinolysis, 1999, 10, 531.	0.5	0
341	Anticoagulants, antiplatelets and thrombolytics. British Journal of Clinical Pharmacology, 2004, 58, 442-442.	1.1	0
342	AR-C69931MX. , 2007, , 1-4.		0

#	Article	IF	Citations
343	Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease. , 0, , 1-14.		0
344	ST Elevation Acute Coronary Syndromes in PLATO. Circulation, 2011, , 1.	1.6	0
345	Republished Education in Heart: New P2Y12 inhibitors. Postgraduate Medical Journal, 2012, 88, 49-54.	0.9	0
346	Contemporary Management of ST-Segment Elevation Myocardial Infarction. Hospital Practice (1995), 2012, 40, 224-231.	0.5	0
347	ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /Ove	0.2	0
348	ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10	0.2	0
349	Response to Letter Regarding Article, "Ticagrelor in Patients With Acute Coronary Syndromes and Stroke: Interpretation of Subgroups in Clinical Trials". Stroke, 2013, 44, e95-e96.	1.0	0
350	Beware the normal angiogram. Clinical Medicine, 2014, 14, 323.3-324.	0.8	0
351	203â€…Ticagrelor and Clopidogrel Attenuate the Prothrombotic State induced by Bacterial Endotoxaemia. Heart, 2015, 101, A112.1-A112.	1.2	0
352	27â€…Impact of Culprit Versus Non-Culprit Angiography Strategy on Primary PCI Door to Balloon Times. Heart, 2016, 102, A18-A18.	1.2	0
353	Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age?. JACC: Cardiovascular Interventions, 2019, 12, 993-994.	1.1	0
354	Selatogrel and other P2Y12 inhibitorsâ€™ putative off-target effects. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	0
355	The conundrum of simultaneous antiplatelet and anticoagulant therapy: how to solve it?. , 2021, , 193-199.		0
356	ARL67085. , 2007, , 1-3.		0
357	ARL66096. , 2007, , 1-2.		0
358	Prasugrel. , 2009, , 1-4.		0
359	MRS 2395. , 2009, , 1-2.		0
360	Abstract 20657: Plasma MicroRNAs Correlate With Platelet Reactivity in Patients With Acute Coronary Syndrome: Association With Platelet Function. Circulation, 2014, 130, .	1.6	0

#	Article	IF	Citations
361	Abstract 20470: Lower Mortality and Stent Thrombosis Rates Associated With Introduction of Potent P2Y12 Inhibitors in Patients With Acute Coronary Syndromes. Circulation, 2014, 130, .	1.6	0
362	Abstract 13290: GDF-15 at One Month After an Acute Coronary Syndrome is Associated With Increased Risk of Major Bleeding - A PLATO Biomarker Substudy. Circulation, 2015, 132, .	1.6	0
363	Abstract 17121: Reduction in Total Cardiovascular Events With Long-term Use of Ticagrelor in Patients With Prior Myocardial Infarction in the PEGASUS-TIMI 54 Trial. Circulation, 2015, 132, .	1.6	0
364	Platelets in Acute Coronary Syndromes. , 2017, , 1015-1028.		0
365	Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2020, 142, .	1.6	0